33 results match your criteria: "Swanston Centre[Affiliation]"
Aust N Z J Psychiatry
April 2005
Barwon Health and The Geewong Clinic, Swanston Centre, PO Box 281, Geelong, Victoria 3220, Australia.
Objective: To explore diagnostic and treatment issues concerning bipolar mixed states.
Method: Bipolar mixed states are described and concerns about diagnostic and treatment difficulties are summarized and discussed.
Result: Mixed states can present with equal admixtures of depressive or manic symptoms, or more commonly one component predominates.
Bipolar Disord
February 2005
Department of Clinical and Biomedical Sciences, University of Melbourne, Swanston Centre, Geelong, Victoria, Australia.
Objectives: To review the current knowledge of bipolar II disorder.
Methods: Literature was reviewed after conducting a Medline search and a hand search of relevant literature.
Results: Bipolar II disorder is a common disorder, with a prevalence of approximately 3-5%.
Drugs
April 2005
Department of Clinical and Biomedical Sciences, The University of Melbourne, Swanston Centre, PO Box 281, Geelong, VIC 3220, Australia.
Bipolar disorder is a severe and recurrent disorder. Atypical antipsychotics have emerged as both an alternative and adjunct to conventional mood stabilisers. The manic phase of the illness is the best studied, and it appears that a class effect with regards to efficacy is present in both monotherapy and augmentation studies.
View Article and Find Full Text PDFJ Eval Clin Pract
November 2004
Clinical and Biomedical Sciences, University of Melbourne, Community and Mental Health, Barwon Health, Swanston Centre, Geelong, Victoria, Australia.
Objective: To evaluate outcome and client and referrer satisfaction with the service provided by a Mood and Anxiety Disorders Unit (MADU).
Method: MADU was a specialized clinical service for the assessment and management of individuals suffering with affective and anxiety disorders. Clients were referred to MADU from a variety of health service providers.
Expert Opin Drug Saf
May 2004
Department of Clinical and Biomedical Sciences, University of Melbourne, Community and Mental Health, Barwon Health, Swanston Centre, Geelong, Victoria, Australia.
Treating bipolar disorder in women during reproduction presents a significant challenge to the physician. The pharmaceutical agents most commonly used for treating bipolar disorder have been associated with adverse effects when used during pregnancy and breastfeeding. Of particular concern has been the association of lithium with cardiac malformations, and the association of carbamazepine and valproate with neural tube defects including spina bifida.
View Article and Find Full Text PDFHum Psychopharmacol
August 2003
Barwon Health Mental Health, Swanston Centre, PO Box 281, Geelong, Victoria 3220, Australia.
The pharmacological management of violence and aggression is a common and substantial clinical dilemma in the emergency psychiatric situation. A literature search was conducted through PubMed and using the Cochrane Library. This was followed by a manual search of selected literature.
View Article and Find Full Text PDFExpert Rev Neurother
July 2003
Barwon Health and Geelong Clinic, Department of Clinical and Biomedical Sciences, University of Melbourne, Swanston Centre, PO Box 281, Geelong Victoria 3220, Australia.
A developing concept is that antidepressant strategies which combine multiple mechanisms of action may have advantages over agents with single mechanisms. Duloxetine is a novel potent dual reuptake inhibitor of noradrenaline and serotonin. The antidepressant efficacy of duloxetine is reviewed in three trials.
View Article and Find Full Text PDFAust N Z J Psychiatry
October 2001
Barwon Health: Community and Mental Health, Swanston Centre, Corner Swanston and Myers Streets, Geelong, Victoria 3220, Australia.
Objective: The objective of this study was to examine the prevalence of psychiatric disorders in a group of patients who had recently entered a methadone maintenance programme.
Method: A total of 62 patients were interviewed using the Composite International Diagnostic Interview (CIDI) within 6 months of commencing methadone maintenance. The CIDI was used to establish symptoms of psychiatric illness at interview and in the 12 months prior.